Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

April’s top stories: SynbiCITE’s synthetic biology foundry, Omeros’s phase II clinical trial of OMS721

SynbiCITE opened a commercial synthetic biology foundry at Imperial College London, and Omeros began dosing patients in its new Phase ll clinical trial of OMS721 in corticosteroid-dependent renal diseases. Drugdevelopment-technology.com wraps up the key headlines from April 2016.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free


Go Top